Good evening :)
$
₹
Bio-Techne Corp

Bio-Techne Corp

TECH

NASDAQ
Asset Logo

Bio-Techne Corp

TECH

NASDAQ
$72.290.06% (-0.04)
$
₹
$72.290.06% (-0.04)
High
—
—
Low
—
—
Returns
—
—
1D
1W
1M
1Y
5Y
Max
Loading...
1D
1W
1M
1Y
5Y
Max

Healthcare

Biotechnology

Large Cap

With a market cap of $11.3B the stock is ranked 918

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

62.30
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

5.36
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$1.16
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

2.09
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

14.97%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

0.44%

Analyst Ratings & Forecast
Analyst Ratings & Forecast

Based on 15 analysts' reports

Buy
10 analysts
Hold
5 analysts
Sell
0 analyst

Analysts expect a -2.23% price downside over the next year

Current Price$72.29
Target Price$70.72

Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.
Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. It operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. Its Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Peers

Peers

Thermo Fisher Scientific Inc
TMO
Thermo Fisher Scientific Inc
P/E Ratio
32.99
32.99
1Y Return
35.18%
35.18%
Buy Reco %
80.64
80.64
IQVIA Holdings Inc
IQV
IQVIA Holdings Inc
P/E Ratio
33.61
33.61
1Y Return
45.00%
45.00%
Buy Reco %
69.56
69.56
Agilent Technologies Inc
A
Agilent Technologies Inc
P/E Ratio
28.95
28.95
1Y Return
19.85%
19.85%
Buy Reco %
82.35
82.35
Waters Corporation
WAT
Waters Corporation
P/E Ratio
104.27
104.27
1Y Return
39.47%
39.47%
Buy Reco %
31.81
31.81
Illumina Inc
ILMN
Illumina Inc
P/E Ratio
38.77
38.77
1Y Return
120.26%
120.26%
Buy Reco %
55.00
55.00

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Bio-Techne Corp 62.305.362.09
Thermo Fisher Scientific Inc32.994.281.81
IQVIA Holdings Inc33.616.980.95

Price Comparison

Price Comparison

1 Month

1 Year

5 Years

Loading...

Financials

Financials

Income

Balance Sheet

Cash Flow

286.5
38.1
295.8
38
311.4
51
321.1
54.6
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue303.42306.09289.45297.03316.18316.96286.55295.87311.41321.19
Net Income49.0540.5833.634.8922.58-17.6738.183851.0554.61
Net Profit Margin16.16%13.25%11.60%11.74%7.14%-5.57%13.32%12.84%16.39%17.00%
See CostsAll values in $ Million

Frequently asked questions

Frequently asked questions

  1. Bio-Techne Corp (TECH) share price today is $72.29 as of September 16, 2026 at 9:16 PM IST. The stock touched a day high of $72.32 and a day low of $72.22.

  2. Bio-Techne Corp stock trades on NASDAQ under the ticker symbol TECH.

  3. Bio-Techne Corp's market capitalization is $11.33B as of September 16, 2026 at 9:16 PM IST.

  4. Bio-Techne Corp's price-to-earnings (P/E) ratio is 62.30 as of September 16, 2026.

  5. Bio-Techne Corp's price-to-book (P/B) ratio is 5.36 as of September 16, 2026.

  6. Yes, Bio-Techne Corp pays a dividend, with a current dividend yield of 0.44%.

  7. Yes, You can buy Bio-Techne Corp shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  8. Indian investors can buy Bio-Techne Corp shares in three steps: 1. Search Bio-Techne Corp on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  9. Since Bio-Techne Corp trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  10. Indian investors can start investing in Bio-Techne Corp (TECH) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.1383 shares at the current price of $72.29.

Loading...